BioStem Technologies, Inc. is a Pompano Beach, Florida-headquartered regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, with the Company's proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies designed to optimize the preservation of natural tissue properties for clinical use across wound care, surgical, and orthopedic applications. For the second quarter ended June 30, 2026, the Company generated net revenue of $7.9 million, representing 29 percent sequential growth from $6.1 million in Q1 2026, though down 28.2 percent from $11.0 million in the prior-year quarter. The revenue was primarily driven by Neox® and Clarix® product sales, with hospital revenue of $6.7 million (up from $5.7 million in Q1) and physician office revenue of $1.1 million (up from $0.8 million). Gross profit of $4.8 million produced a gross margin of 61 percent (flat sequentially from Q1, down from 94 percent in Q2 2025). GAAP net loss was $(9.0) million ($(0.52) per share) compared to a negligible profit of $10.6 thousand in Q2 2025, and Adjusted EBITDA loss was $(4.6) million compared to $2.5 million positive in Q2 2025. The Company completed its uplisting to the Nasdaq Capital Market on August 7, 2026, closed a $2.5 million private placement with its first institutional investor, resolved $5.3 million in outstanding debt, and raised full-year 2026 revenue guidance to $26-29 million (from $25-29 million).
The investment thesis rests on three variables. The commercial scaling trajectory is the load-bearing revenue variable, with Q2 2026 sequential revenue growth of 29 percent ($7.9M vs $6.1M Q1) driven by hospital channel expansion ($6.7M vs $5.7M Q1) and the direct sales force scaling, and the strategic intent is to sustain the sequential growth trajectory toward the $26-29 million full-year guidance. The Nasdaq uplisting and capital access is the load-bearing capital markets variable, with the August 7, 2026 uplisting to Nasdaq Capital Market and the $2.5 million private placement with the first institutional investor providing enhanced visibility and capital access, and the strategic intent is to leverage the public currency for further growth financing. The product portfolio and IP expansion is the load-bearing product variable, with the Neox®/Clarix®/VENDAJE®/American Amnion™ portfolio, the eight new U.S. design patents on fenestrated human placental allograft technology, and the AATB/cGTP/cGMP accreditations creating a differentiated product moat, and the strategic intent is to continue expanding the IP portfolio and product applications.